table of content
Table of Contents
1 Research Methodology and Statistical Scope
1.1 Market Definition and Statistical Scope of Spinal Muscular Atrophy Medicine
1.2 Key Market Segments
1.2.1 Spinal Muscular Atrophy Medicine Segment by Type
1.2.2 Spinal Muscular Atrophy Medicine Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 Spinal Muscular Atrophy Medicine Market Overview
2.1 Global Market Overview
2.1.1 Global Spinal Muscular Atrophy Medicine Market Size (M USD) Estimates and Forecasts (2019-2030)
2.1.2 Global Spinal Muscular Atrophy Medicine Sales Estimates and Forecasts (2019-2030)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 Spinal Muscular Atrophy Medicine Market Competitive Landscape
3.1 Global Spinal Muscular Atrophy Medicine Sales by Manufacturers (2019-2024)
3.2 Global Spinal Muscular Atrophy Medicine Revenue Market Share by Manufacturers (2019-2024)
3.3 Spinal Muscular Atrophy Medicine Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4 Global Spinal Muscular Atrophy Medicine Average Price by Manufacturers (2019-2024)
3.5 Manufacturers Spinal Muscular Atrophy Medicine Sales Sites, Area Served, Product Type
3.6 Spinal Muscular Atrophy Medicine Market Competitive Situation and Trends
3.6.1 Spinal Muscular Atrophy Medicine Market Concentration Rate
3.6.2 Global 5 and 10 Largest Spinal Muscular Atrophy Medicine Players Market Share by Revenue
3.6.3 Mergers & Acquisitions, Expansion
4 Spinal Muscular Atrophy Medicine Industry Chain Analysis
4.1 Spinal Muscular Atrophy Medicine Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 The Development and Dynamics of Spinal Muscular Atrophy Medicine Market
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Market Restraints
5.5 Industry News
5.5.1 New Product Developments
5.5.2 Mergers & Acquisitions
5.5.3 Expansions
5.5.4 Collaboration/Supply Contracts
5.6 Industry Policies
6 Spinal Muscular Atrophy Medicine Market Segmentation by Type
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Spinal Muscular Atrophy Medicine Sales Market Share by Type (2019-2024)
6.3 Global Spinal Muscular Atrophy Medicine Market Size Market Share by Type (2019-2024)
6.4 Global Spinal Muscular Atrophy Medicine Price by Type (2019-2024)
7 Spinal Muscular Atrophy Medicine Market Segmentation by Application
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Spinal Muscular Atrophy Medicine Market Sales by Application (2019-2024)
7.3 Global Spinal Muscular Atrophy Medicine Market Size (M USD) by Application (2019-2024)
7.4 Global Spinal Muscular Atrophy Medicine Sales Growth Rate by Application (2019-2024)
8 Spinal Muscular Atrophy Medicine Market Segmentation by Region
8.1 Global Spinal Muscular Atrophy Medicine Sales by Region
8.1.1 Global Spinal Muscular Atrophy Medicine Sales by Region
8.1.2 Global Spinal Muscular Atrophy Medicine Sales Market Share by Region
8.2 North America
8.2.1 North America Spinal Muscular Atrophy Medicine Sales by Country
8.2.2 U.S.
8.2.3 Canada
8.2.4 Mexico
8.3 Europe
8.3.1 Europe Spinal Muscular Atrophy Medicine Sales by Country
8.3.2 Germany
8.3.3 France
8.3.4 U.K.
8.3.5 Italy
8.3.6 Russia
8.4 Asia Pacific
8.4.1 Asia Pacific Spinal Muscular Atrophy Medicine Sales by Region
8.4.2 China
8.4.3 Japan
8.4.4 South Korea
8.4.5 India
8.4.6 Southeast Asia
8.5 South America
8.5.1 South America Spinal Muscular Atrophy Medicine Sales by Country
8.5.2 Brazil
8.5.3 Argentina
8.5.4 Columbia
8.6 Middle East and Africa
8.6.1 Middle East and Africa Spinal Muscular Atrophy Medicine Sales by Region
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Egypt
8.6.5 Nigeria
8.6.6 South Africa
9 Key Companies Profile
9.1 Astellas Pharma Inc.
9.1.1 Astellas Pharma Inc. Spinal Muscular Atrophy Medicine Basic Information
9.1.2 Astellas Pharma Inc. Spinal Muscular Atrophy Medicine Product Overview
9.1.3 Astellas Pharma Inc. Spinal Muscular Atrophy Medicine Product Market Performance
9.1.4 Astellas Pharma Inc. Business Overview
9.1.5 Astellas Pharma Inc. Spinal Muscular Atrophy Medicine SWOT Analysis
9.1.6 Astellas Pharma Inc. Recent Developments
9.2 AveXis, Inc.
9.2.1 AveXis, Inc. Spinal Muscular Atrophy Medicine Basic Information
9.2.2 AveXis, Inc. Spinal Muscular Atrophy Medicine Product Overview
9.2.3 AveXis, Inc. Spinal Muscular Atrophy Medicine Product Market Performance
9.2.4 AveXis, Inc. Business Overview
9.2.5 AveXis, Inc. Spinal Muscular Atrophy Medicine SWOT Analysis
9.2.6 AveXis, Inc. Recent Developments
9.3 Bioblast Pharma Ltd.
9.3.1 Bioblast Pharma Ltd. Spinal Muscular Atrophy Medicine Basic Information
9.3.2 Bioblast Pharma Ltd. Spinal Muscular Atrophy Medicine Product Overview
9.3.3 Bioblast Pharma Ltd. Spinal Muscular Atrophy Medicine Product Market Performance
9.3.4 Bioblast Pharma Ltd. Spinal Muscular Atrophy Medicine SWOT Analysis
9.3.5 Bioblast Pharma Ltd. Business Overview
9.3.6 Bioblast Pharma Ltd. Recent Developments
9.4 Cytokinetics, Inc. 24
9.4.1 Cytokinetics, Inc. 24 Spinal Muscular Atrophy Medicine Basic Information
9.4.2 Cytokinetics, Inc. 24 Spinal Muscular Atrophy Medicine Product Overview
9.4.3 Cytokinetics, Inc. 24 Spinal Muscular Atrophy Medicine Product Market Performance
9.4.4 Cytokinetics, Inc. 24 Business Overview
9.4.5 Cytokinetics, Inc. 24 Recent Developments
9.5 F. Hoffmann-La Roche Ltd.
9.5.1 F. Hoffmann-La Roche Ltd. Spinal Muscular Atrophy Medicine Basic Information
9.5.2 F. Hoffmann-La Roche Ltd. Spinal Muscular Atrophy Medicine Product Overview
9.5.3 F. Hoffmann-La Roche Ltd. Spinal Muscular Atrophy Medicine Product Market Performance
9.5.4 F. Hoffmann-La Roche Ltd. Business Overview
9.5.5 F. Hoffmann-La Roche Ltd. Recent Developments
9.6 Genethon
9.6.1 Genethon Spinal Muscular Atrophy Medicine Basic Information
9.6.2 Genethon Spinal Muscular Atrophy Medicine Product Overview
9.6.3 Genethon Spinal Muscular Atrophy Medicine Product Market Performance
9.6.4 Genethon Business Overview
9.6.5 Genethon Recent Developments
9.7 Genzyme Corporation
9.7.1 Genzyme Corporation Spinal Muscular Atrophy Medicine Basic Information
9.7.2 Genzyme Corporation Spinal Muscular Atrophy Medicine Product Overview
9.7.3 Genzyme Corporation Spinal Muscular Atrophy Medicine Product Market Performance
9.7.4 Genzyme Corporation Business Overview
9.7.5 Genzyme Corporation Recent Developments
9.8 GMP-Orphan SAS
9.8.1 GMP-Orphan SAS Spinal Muscular Atrophy Medicine Basic Information
9.8.2 GMP-Orphan SAS Spinal Muscular Atrophy Medicine Product Overview
9.8.3 GMP-Orphan SAS Spinal Muscular Atrophy Medicine Product Market Performance
9.8.4 GMP-Orphan SAS Business Overview
9.8.5 GMP-Orphan SAS Recent Developments
9.9 Ionis Pharmaceuticals, Inc.
9.9.1 Ionis Pharmaceuticals, Inc. Spinal Muscular Atrophy Medicine Basic Information
9.9.2 Ionis Pharmaceuticals, Inc. Spinal Muscular Atrophy Medicine Product Overview
9.9.3 Ionis Pharmaceuticals, Inc. Spinal Muscular Atrophy Medicine Product Market Performance
9.9.4 Ionis Pharmaceuticals, Inc. Business Overview
9.9.5 Ionis Pharmaceuticals, Inc. Recent Developments
9.10 Longevity Biotech, Inc
9.10.1 Longevity Biotech, Inc Spinal Muscular Atrophy Medicine Basic Information
9.10.2 Longevity Biotech, Inc Spinal Muscular Atrophy Medicine Product Overview
9.10.3 Longevity Biotech, Inc Spinal Muscular Atrophy Medicine Product Market Performance
9.10.4 Longevity Biotech, Inc Business Overview
9.10.5 Longevity Biotech, Inc Recent Developments
9.11 Neurodyn Inc.
9.11.1 Neurodyn Inc. Spinal Muscular Atrophy Medicine Basic Information
9.11.2 Neurodyn Inc. Spinal Muscular Atrophy Medicine Product Overview
9.11.3 Neurodyn Inc. Spinal Muscular Atrophy Medicine Product Market Performance
9.11.4 Neurodyn Inc. Business Overview
9.11.5 Neurodyn Inc. Recent Developments
9.12 Neurotune AG
9.12.1 Neurotune AG Spinal Muscular Atrophy Medicine Basic Information
9.12.2 Neurotune AG Spinal Muscular Atrophy Medicine Product Overview
9.12.3 Neurotune AG Spinal Muscular Atrophy Medicine Product Market Performance
9.12.4 Neurotune AG Business Overview
9.12.5 Neurotune AG Recent Developments
9.13 Novartis AG
9.13.1 Novartis AG Spinal Muscular Atrophy Medicine Basic Information
9.13.2 Novartis AG Spinal Muscular Atrophy Medicine Product Overview
9.13.3 Novartis AG Spinal Muscular Atrophy Medicine Product Market Performance
9.13.4 Novartis AG Business Overview
9.13.5 Novartis AG Recent Developments
9.14 Sarepta Therapeutics, Inc.
9.14.1 Sarepta Therapeutics, Inc. Spinal Muscular Atrophy Medicine Basic Information
9.14.2 Sarepta Therapeutics, Inc. Spinal Muscular Atrophy Medicine Product Overview
9.14.3 Sarepta Therapeutics, Inc. Spinal Muscular Atrophy Medicine Product Market Performance
9.14.4 Sarepta Therapeutics, Inc. Business Overview
9.14.5 Sarepta Therapeutics, Inc. Recent Developments
9.15 Voyager Therapeutics, Inc.
9.15.1 Voyager Therapeutics, Inc. Spinal Muscular Atrophy Medicine Basic Information
9.15.2 Voyager Therapeutics, Inc. Spinal Muscular Atrophy Medicine Product Overview
9.15.3 Voyager Therapeutics, Inc. Spinal Muscular Atrophy Medicine Product Market Performance
9.15.4 Voyager Therapeutics, Inc. Business Overview
9.15.5 Voyager Therapeutics, Inc. Recent Developments
9.16 Vybion, Inc.
9.16.1 Vybion, Inc. Spinal Muscular Atrophy Medicine Basic Information
9.16.2 Vybion, Inc. Spinal Muscular Atrophy Medicine Product Overview
9.16.3 Vybion, Inc. Spinal Muscular Atrophy Medicine Product Market Performance
9.16.4 Vybion, Inc. Business Overview
9.16.5 Vybion, Inc. Recent Developments
9.17 WAVE Life Sciences Ltd.
9.17.1 WAVE Life Sciences Ltd. Spinal Muscular Atrophy Medicine Basic Information
9.17.2 WAVE Life Sciences Ltd. Spinal Muscular Atrophy Medicine Product Overview
9.17.3 WAVE Life Sciences Ltd. Spinal Muscular Atrophy Medicine Product Market Performance
9.17.4 WAVE Life Sciences Ltd. Business Overview
9.17.5 WAVE Life Sciences Ltd. Recent Developments
10 Spinal Muscular Atrophy Medicine Market Forecast by Region
10.1 Global Spinal Muscular Atrophy Medicine Market Size Forecast
10.2 Global Spinal Muscular Atrophy Medicine Market Forecast by Region
10.2.1 North America Market Size Forecast by Country
10.2.2 Europe Spinal Muscular Atrophy Medicine Market Size Forecast by Country
10.2.3 Asia Pacific Spinal Muscular Atrophy Medicine Market Size Forecast by Region
10.2.4 South America Spinal Muscular Atrophy Medicine Market Size Forecast by Country
10.2.5 Middle East and Africa Forecasted Consumption of Spinal Muscular Atrophy Medicine by Country
11 Forecast Market by Type and by Application (2025-2030)
11.1 Global Spinal Muscular Atrophy Medicine Market Forecast by Type (2025-2030)
11.1.1 Global Forecasted Sales of Spinal Muscular Atrophy Medicine by Type (2025-2030)
11.1.2 Global Spinal Muscular Atrophy Medicine Market Size Forecast by Type (2025-2030)
11.1.3 Global Forecasted Price of Spinal Muscular Atrophy Medicine by Type (2025-2030)
11.2 Global Spinal Muscular Atrophy Medicine Market Forecast by Application (2025-2030)
11.2.1 Global Spinal Muscular Atrophy Medicine Sales (Kilotons) Forecast by Application
11.2.2 Global Spinal Muscular Atrophy Medicine Market Size (M USD) Forecast by Application (2025-2030)
12 Conclusion and Key Findings
